Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients b...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 March 2015
|
| In: |
EMBO molecular medicine
Year: 2015, Jahrgang: 7, Heft: 5, Pages: 562-576 |
| ISSN: | 1757-4684 |
| DOI: | 10.15252/emmm.201505047 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.15252/emmm.201505047 Verlag, kostenfrei, Volltext: http://embomolmed.embopress.org/content/7/5/562 
|
| Verfasserangaben: | Michael Gramlich, Luna Simona Pane, Qifeng Zhou, Zhifen Chen, Marta Murgia, Sonja Schötterl, Alexander Goedel, Katja Metzger, Thomas Brade, Elvira Parrotta, Martin Schaller, Brenda Gerull, Ludwig Thierfelder, Annemieke Aartsma‐Rus, Siegfried Labeit, John J. Atherton, Julie McGaughran, Richard P. Harvey, Daniel Sinnecker, Matthias Mann, Karl-Ludwig Laugwitz, Meinrad Paul Gawaz and Alessandra Moretti |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1585061506 | ||
| 003 | DE-627 | ||
| 005 | 20230427161342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181211s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15252/emmm.201505047 |2 doi | |
| 035 | |a (DE-627)1585061506 | ||
| 035 | |a (DE-576)515061506 | ||
| 035 | |a (DE-599)BSZ515061506 | ||
| 035 | |a (OCoLC)1341026891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gramlich, Michael |d 1975- |e VerfasserIn |0 (DE-588)131363875 |0 (DE-627)508485797 |0 (DE-576)298430789 |4 aut | |
| 245 | 1 | 0 | |a Antisense‐mediated exon skipping |b a therapeutic strategy for titin‐based dilated cardiomyopathy |c Michael Gramlich, Luna Simona Pane, Qifeng Zhou, Zhifen Chen, Marta Murgia, Sonja Schötterl, Alexander Goedel, Katja Metzger, Thomas Brade, Elvira Parrotta, Martin Schaller, Brenda Gerull, Ludwig Thierfelder, Annemieke Aartsma‐Rus, Siegfried Labeit, John J. Atherton, Julie McGaughran, Richard P. Harvey, Daniel Sinnecker, Matthias Mann, Karl-Ludwig Laugwitz, Meinrad Paul Gawaz and Alessandra Moretti |
| 264 | 1 | |c 10 March 2015 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.12.2018 | ||
| 520 | |a Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients but heart transplantation. Here, we show the beneficial potential of reframing titin transcripts by antisense oligonucleotide (AON)‐mediated exon skipping in human and murine models of DCM carrying a previously identified autosomal‐dominant frameshift mutation in titin exon 326. Correction of TTN reading frame in patient‐specific cardiomyocytes derived from induced pluripotent stem cells rescued defective myofibril assembly and stability and normalized the sarcomeric protein expression. AON treatment in Ttn knock‐in mice improved sarcomere formation and contractile performance in homozygous embryos and prevented the development of the DCM phenotype in heterozygous animals. These results demonstrate that disruption of the titin reading frame due to a truncating DCM mutation can be restored by exon skipping in both patient cardiomyocytes in vitro and mouse heart in vivo, indicating RNA‐based strategies as a potential treatment option for DCM. | ||
| 650 | 4 | |a dilated cardiomyopathy | |
| 650 | 4 | |a exon skipping | |
| 650 | 4 | |a induced pluripotent stem cells | |
| 650 | 4 | |a titin | |
| 700 | 1 | |a Labeit, Siegfried |d 1960- |e VerfasserIn |0 (DE-588)1033566837 |0 (DE-627)741562375 |0 (DE-576)381187314 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a European Molecular Biology Organization |t EMBO molecular medicine |d [London] : Nature Publishing Group UK, 2009 |g 7(2015), 5, Seite 562-576 |h Online-Ressource |w (DE-627)594772761 |w (DE-600)2485479-7 |w (DE-576)305355961 |x 1757-4684 |7 nnas |
| 773 | 1 | 8 | |g volume:7 |g year:2015 |g number:5 |g pages:562-576 |g extent:15 |a Antisense‐mediated exon skipping a therapeutic strategy for titin‐based dilated cardiomyopathy |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15252/emmm.201505047 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://embomolmed.embopress.org/content/7/5/562 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181211 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1033566837 |a Labeit, Siegfried |m 1033566837:Labeit, Siegfried |d 60000 |d 61600 |d 50000 |e 60000PL1033566837 |e 61600PL1033566837 |e 50000PL1033566837 |k 0/60000/ |k 1/60000/61600/ |k 0/50000/ |p 15 | ||
| 999 | |a KXP-PPN1585061506 |e 3037375531 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"15 S."}],"id":{"eki":["1585061506"],"doi":["10.15252/emmm.201505047"]},"relHost":[{"note":["Gesehen am 5. November 2022","Fortsetzung der Druck-Ausgabe"],"corporate":[{"display":"European Molecular Biology Organization","role":"aut"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"European Molecular Biology OrganizationEMBO molecular medicine","id":{"issn":["1757-4684"],"zdb":["2485479-7"],"doi":["10.1002/(ISSN)1757-4684"],"eki":["594772761"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"[London] ; Heidelberg ; Weinheim","publisher":"Nature Publishing Group UK ; EMBO Press ; Wiley-VCH","dateIssuedDisp":"[2009]-"}],"recId":"594772761","name":{"displayForm":["European Molecular Biology Organization (EMBO)"]},"pubHistory":["Vol. 1, No. 1 (Apr 1, 2009)-"],"part":{"pages":"562-576","extent":"15","issue":"5","volume":"7","text":"7(2015), 5, Seite 562-576","year":"2015"},"language":["eng"],"title":[{"title_sort":"EMBO molecular medicine","title":"EMBO molecular medicine"}]}],"note":["Gesehen am 11.12.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"10 March 2015","dateIssuedKey":"2015"}],"recId":"1585061506","person":[{"family":"Gramlich","display":"Gramlich, Michael","role":"aut","given":"Michael"},{"display":"Labeit, Siegfried","role":"aut","given":"Siegfried","family":"Labeit"}],"name":{"displayForm":["Michael Gramlich, Luna Simona Pane, Qifeng Zhou, Zhifen Chen, Marta Murgia, Sonja Schötterl, Alexander Goedel, Katja Metzger, Thomas Brade, Elvira Parrotta, Martin Schaller, Brenda Gerull, Ludwig Thierfelder, Annemieke Aartsma‐Rus, Siegfried Labeit, John J. Atherton, Julie McGaughran, Richard P. Harvey, Daniel Sinnecker, Matthias Mann, Karl-Ludwig Laugwitz, Meinrad Paul Gawaz and Alessandra Moretti"]},"title":[{"title_sort":"Antisense‐mediated exon skipping","title":"Antisense‐mediated exon skipping","subtitle":"a therapeutic strategy for titin‐based dilated cardiomyopathy"}],"language":["eng"]} | ||
| SRT | |a GRAMLICHMIANTISENSEM1020 | ||